Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
1. A method of treating cancer, wherein said cancer is selected from breast cancer and prostate cancer, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a therapeutic nanoparticle; wherein said therapeutic nanoparticle comprises:
a therapeutic agent selected from the group consisting of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyI)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea and pharmaceutically acceptable salt thereof;
a polymer selected from the group consisting of diblock poly(lactic) acid-poly (ethylene)glycol (PLA-PEG) copolymer, diblock poly(lactic acid-co-glycolic acid)-poly (ethylene)glycol (PLGA-PEG) copolymer, and combinations thereof; and
a substantially hydrophobic acid selected from the group consisting of dioctyl sulfosuccinic acid, 1-hydroxy-2-naphthoic acid, dodecylsulfuric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, pamoic acid, undecanoic acid, and combinations thereof;
wherein the substantially hydrophobic acid and the therapeutic agent form a hydrophobic ion pair that is encapsulated in the therapeutic nanoparticle;
wherein the hydrophobic ion pair is dispersed throughout a polymeric matrix comprising the polymer; and
wherein PLA-PEG-GL is additionally present, wherein targeting ligand GL has the following structure:
2. The method of claim 1 , wherein the cancer is breast cancer.
3. The method of claim 1 , wherein the cancer is prostate cancer.